(Q38029394)

27 August 2017

title

The development of denosumab for the treatment of diseases of bone loss and cancer-induced bone destruction (English)

1 reference

27 August 2017

Carsten Goessl

1

1 reference

27 August 2017

Leonid Katz

2

1 reference

27 August 2017

William C Dougall

3

1 reference

27 August 2017

Paul J Kostenuik

4

1 reference

27 August 2017

Holly Brenza Zoog

5

1 reference

27 August 2017

Ada Braun

6

1 reference

27 August 2017

Roger Dansey

7

1 reference

27 August 2017

Rachel B Wagman

8

1 reference

27 August 2017

language of work or name

English

0 references

publication date

25 July 2012

1 reference

Annals of the New York Academy of Sciences

27 August 2017

published in

1 reference

27 August 2017

volume

1263

1 reference

27 August 2017

page(s)

29-40

1 reference

RANK is essential for osteoclast and lymph node development

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06674.X

Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06674.X

Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06674.X

Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06674.X

Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06674.X

Osteoprotegerin: a novel secreted protein involved in the regulation of bone density

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06674.X

osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06674.X

OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06674.X

Soluble RANKL induces high bone turnover and decreases bone volume, density, and strength in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06674.X

Continuous RANKL inhibition in osteoprotegerin transgenic mice and rats suppresses bone resorption without impairing lymphorganogenesis or functional immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06674.X

Regulatory effects of osteoprotegerin on cellular and humoral immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06674.X

Do RANKL inhibitors (denosumab) affect inflammation and immunity?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06674.X

Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06674.X

Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06674.X

Epidemiology and outcomes of osteoporotic fractures

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06674.X

Meta-analysis: excess mortality after hip fracture among older women and men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06674.X

Review of adherence to medications for the treatment of osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06674.X

Adherence to medications for the treatment of osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06674.X

Impact of osteoporosis treatment adherence on fracture rates in North America and Europe.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06674.X

A systematic review of persistence and compliance with bisphosphonates for osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06674.X

Osteoporosis: a still increasing prevalence

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06674.X

Compliance with osteoporosis medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06674.X

Denosumab, a fully human RANKL antibody, reduced bone turnover markers and increased trabecular and cortical bone mass, density, and strength in ovariectomized cynomolgus monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06674.X

Decreased bone remodeling and porosity are associated with improved bone strength in ovariectomized cynomolgus monkeys treated with denosumab, a fully human RANKL antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06674.X

A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06674.X

Denosumab for prevention of fractures in postmenopausal women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06674.X

Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06674.X

Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06674.X

A method to assess the proportion of treatment effect explained by a surrogate endpoint

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06674.X

Relationship between changes in BMD and nonvertebral fracture incidence associated with risedronate: reduction in risk of nonvertebral fracture is not related to change in BMD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06674.X

Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06674.X

Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06674.X

Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06674.X

Intracortical remodelling and porosity in the distal radius and post-mortem femurs of women: a cross-sectional study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06674.X

Microarchitectural deterioration of cortical and trabecular bone: differing effects of denosumab and alendronate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06674.X

Effects of denosumab on bone mineral density and bone turnover in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06674.X

Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06674.X

Bone remodeling in postmenopausal women who discontinued denosumab treatment: off-treatment biopsy study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06674.X

Infections in postmenopausal women with osteoporosis treated with denosumab or placebo: coincidence or causal association?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06674.X

Increased RANK ligand in bone marrow of orchiectomized rats and prevention of their bone loss by the RANK ligand inhibitor osteoprotegerin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06674.X

Orchiectomy upregulates free soluble RANKL in bone marrow of aged rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06674.X

Suppressive function of androgen receptor in bone resorption

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06674.X

Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06674.X

Impact of androgen deprivation therapy on cardiovascular disease and diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06674.X

Fracture risk in men with prostate cancer: a population-based study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06674.X

Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06674.X

Increased fracture rate in women with breast cancer: a review of the hidden risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06674.X

Cancer therapy associated bone loss: implications for hip fractures in mid-life women with breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06674.X

Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06674.X

Denosumab in men receiving androgen-deprivation therapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06674.X

Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06674.X

Clinical features of metastatic bone disease and risk of skeletal morbidity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06674.X

Osteotropic cancers: from primary tumor to bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06674.X

Prostate cancer clinical trial end points: "RECIST"ing a step backwards.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06674.X

Mechanisms of bone metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06674.X

Molecular pathways: osteoclast-dependent and osteoclast-independent roles of the RANKL/RANK/OPG pathway in tumorigenesis and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06674.X

RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06674.X

RANK ligand as a therapeutic target for bone metastases and multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06674.X

Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06674.X

Inhibition of RANKL increases the anti-tumor effect of the EGFR inhibitor panitumumab in a murine model of bone metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06674.X

Combined therapy with the RANKL inhibitor RANK-Fc and rhApo2L/TRAIL/dulanermin reduces bone lesions and skeletal tumor burden in a model of breast cancer skeletal metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06674.X

Control of mammary stem cell function by steroid hormone signalling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06674.X

Two distinct mechanisms underlie progesterone-induced proliferation in the mammary gland.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06674.X

Progesterone induces adult mammary stem cell expansion

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06674.X

RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06674.X

Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06674.X

Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06674.X

Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06674.X

A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06674.X

Denosumab treatment of prostate cancer with bone metastases and increased urine N-telopeptide levels after therapy with intravenous bisphosphonates: results of a randomized phase II trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06674.X

Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06674.X

Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06674.X

Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06674.X

Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06674.X

Androgen-Independent Prostate Cancer Is a Heterogeneous Group of Diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2012.06674.X

10.1111/J.1749-6632.2012.06674.X

21 January 2018

Identifiers

DOI

1 reference

27 August 2017

1 reference